Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on October

Classification of products:

Status	Description
GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
RED	Red-Hospital initiation and continuation only
GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
PURPLE	To be supplied from the appropriate commissioned provider.
NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
nil				
2) New Requests				
Roxadustat	RED			The formulary will reflect the TAG – ICS is the responsible commissioner

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Gefapixant	RED			Private prescriptions only from HUTH under chronic cough clinic
3) New formulations & extensions to use				
Triptorelin 6 monthly (Decapeptyl®)	AMB 1			For new initiations from NLAG.
4) Products considered by NICE				
TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides			Y	Decision on classification deferred until application and updated place in therapy
TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis	RED			The formulary will reflect the TAG – ICS is the responsible commissioner for adults and NHSE is the responsible commissioner for paediatrics

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
TA820: Brolucizumab for treating diabetic macular oedema	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner Neither HUTH or NLAG are commissioned to provide this
TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner
HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency	RED			The formulary will reflect the HST – NHSE is the responsible commissioner Neither HUTH or NLAG are commissioned to provide this service
TA808: Fenfluramine for treating seizures associated with Dravet syndrome	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner HUTH is commissioned for this in adults
TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner
TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner
TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies	RED			The formulary will reflect the TAG – NHSE is the responsible commissioner
TA821: Avalglucosidase alfa for treating Pompe disease				The formulary will reflect the TAG – NHSE is the responsible commissioner
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
Posaconazole	RED			

The following guidelines were presented to and approved at the October 2022 meeting of the APC:

- Inclisiran Amber 1 guidance
- Lipid guidance

The following Green+ drug information leaflets were presented to and approved at the October 2022 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the October 2022 meeting of the APC:

- Dementia SCF Hull and East Riding only

Other documents presented to and approved at the October 2022 meeting of the APC:

- Joint formulary chapter 2